Annotation (Toggle Detail/Summary View) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene-Chemical Interaction Annotations
Gene-Chemical Interaction AnnotationsTerm | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (R)-mevalonic acid | multiple interactions | EXP | | 6480464 | Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]] | CTD | PMID:14500290 | (R)-mevalonic acid | multiple interactions | ISO | RGD:1307751 | 6480464 | Mevalonic Acid inhibits the reaction [atorvastatin results in increased expression of SREBF2 mRNA]; more ... | CTD | PMID:12056585 | 17beta-hydroxy-5alpha-androstan-3-one | increases expression | ISO | RGD:730973 | 6480464 | Dihydrotestosterone results in increased expression of SREBF2 mRNA | CTD | PMID:16990341 | 17beta-hydroxy-5alpha-androstan-3-one | increases expression | EXP | | 6480464 | Dihydrotestosterone results in increased expression of SREBF2 mRNA | CTD | PMID:16541421 | 2,2',4,4',5,5'-hexachlorobiphenyl | multiple interactions | ISO | RGD:730973 | 6480464 | Tetrachlorodibenzodioxin inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of SREBF2 mRNA] | CTD | PMID:21851831 | 2,2',4,4',5,5'-hexachlorobiphenyl | decreases expression | ISO | RGD:730973 | 6480464 | 2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of SREBF2 mRNA | CTD | PMID:20005886 | 2,2',4,4',5,5'-hexachlorobiphenyl | decreases expression | ISO | RGD:730973 | 6480464 | 2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of SREBF2 mRNA | CTD | PMID:20005886 PMID:21851831 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:730973 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SREBF2 mRNA | CTD | PMID:20005886 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:730973 | 6480464 | Tetrachlorodibenzodioxin affects the expression of SREBF2 mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1307751 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SREBF2 mRNA | CTD | PMID:21215274 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:730973 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SREBF2 mRNA | CTD | PMID:20005886 PMID:21851831 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:730973 | 6480464 | Tetrachlorodibenzodioxin inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of SREBF2 mRNA] | CTD | PMID:21851831 | 2,6-dinitrotoluene | affects expression | ISO | RGD:1307751 | 6480464 | 2,6-dinitrotoluene affects the expression of SREBF2 mRNA | CTD | PMID:21346803 | 25-hydroxycholesterol | multiple interactions | EXP | | 6480464 | 25-hydroxycholesterol inhibits the reaction [resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein]; more ... | CTD | PMID:22153697 | 25-hydroxycholesterol | multiple interactions | EXP | | 6480464 | Clozapine inhibits the reaction [25-hydroxycholesterol results in decreased activity of SREBF2 protein] | CTD | PMID:17052361 | 25-hydroxycholesterol | decreases activity | EXP | | 6480464 | 25-hydroxycholesterol results in decreased activity of SREBF2 protein | CTD | PMID:17052361 | amitriptyline | multiple interactions | EXP | | 6480464 | Amitriptyline results in increased cleavage of and results in increased activity of SREBF2 protein | CTD | PMID:16324787 | benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of SREBF2 mRNA | CTD | PMID:20106945 | benzo[a]pyrene | multiple interactions | ISO | RGD:730973 | 6480464 | [Benzo(a)pyrene co-treated with XPA gene mutant form co-treated with TRP53 gene mutant form] results in decreased expression of SREBF2 mRNA | CTD | PMID:21715664 | bezafibrate | increases expression | EXP | | 6480464 | Bezafibrate results in increased expression of SREBF2 mRNA | CTD | PMID:14685799 | bisphenol A | affects expression | ISO | RGD:730973 | 6480464 | bisphenol A affects the expression of SREBF2 mRNA; more ... | CTD | PMID:21932408 | cadmium atom | increases expression | ISO | RGD:1307751 | 6480464 | Cadmium results in increased expression of SREBF2 mRNA | CTD | PMID:17066326 | cadmium dichloride | increases expression | ISO | RGD:1307751 | 6480464 | Cadmium Chloride results in increased expression of SREBF2 mRNA | CTD | PMID:17066326 | carbamazepine | decreases expression | EXP | | 6480464 | Carbamazepine results in decreased expression of SREBF2 mRNA | CTD | PMID:21123845 | chlorpromazine | multiple interactions | EXP | | 6480464 | Chlorpromazine results in increased cleavage of and results in increased activity of SREBF2 protein | CTD | PMID:17052361 | cholesterol | multiple interactions | EXP | | 6480464 | [[troglitazone binds to and results in increased activity of PPARG protein] which results in decreased expression of SREBF2 protein] which results in decreased abundance of Cholesterol | CTD | PMID:16946405 | choline | multiple interactions | ISO | RGD:730973 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with RXRA gene mutant form] results in increased expression of SREBF2 mRNA | CTD | PMID:18952117 | citalopram | multiple interactions | EXP | | 6480464 | Citalopram results in increased cleavage of and results in increased activity of SREBF2 protein | CTD | PMID:16324787 | clofibrate | decreases expression | ISO | RGD:1307751 | 6480464 | Clofibrate results in decreased expression of SREBF2 mRNA; more ... | CTD | PMID:17126302 | clomipramine | multiple interactions | EXP | | 6480464 | Clomipramine results in increased cleavage of and results in increased activity of SREBF2 protein | CTD | PMID:16324787 | clozapine | multiple interactions | EXP | | 6480464 | Clozapine inhibits the reaction [25-hydroxycholesterol results in decreased activity of SREBF2 protein]; more ... | CTD | PMID:17052361 | clozapine | increases expression | EXP | | 6480464 | Clozapine results in increased expression of SREBF2 mRNA | CTD | PMID:17052361 | cobalt dichloride | decreases expression | EXP | | 6480464 | cobaltous chloride results in decreased expression of SREBF2 mRNA | CTD | PMID:19320972 | dibutyl phthalate | decreases expression | ISO | RGD:1307751 | 6480464 | Dibutyl Phthalate results in decreased expression of SREBF2 protein | CTD | PMID:21266533 | elemental selenium | increases expression | EXP | | 6480464 | Selenium results in increased expression of SREBF2 mRNA | CTD | PMID:19244175 | ezetimibe | decreases expression | EXP | | 6480464 | ezetimibe results in decreased expression of SREBF2 mRNA | CTD | PMID:16177187 | fenofibrate | increases expression | EXP | | 6480464 | Fenofibrate results in increased expression of SREBF2 mRNA | CTD | PMID:14685799 | gemfibrozil | increases expression | EXP | | 6480464 | Gemfibrozil results in increased expression of SREBF2 mRNA | CTD | PMID:14685799 | haloperidol | multiple interactions | EXP | | 6480464 | Haloperidol results in increased cleavage of and results in increased activity of SREBF2 protein | CTD | PMID:17052361 | hydrogen peroxide | multiple interactions | EXP | | 6480464 | [isoquercitrin co-treated with Hydrogen Peroxide] results in increased cleavage of and results in increased activity of SREBF2 protein; more ... | CTD | PMID:18032389 | imipramine | multiple interactions | EXP | | 6480464 | Imipramine results in increased cleavage of and results in increased activity of SREBF2 protein | CTD | PMID:16324787 | L-methionine | multiple interactions | ISO | RGD:730973 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with RXRA gene mutant form] results in increased expression of SREBF2 mRNA | CTD | PMID:18952117 | lovastatin | increases localization | EXP | | 6480464 | Lovastatin results in increased localization of SREBF2 protein | CTD | PMID:11728391 | mevalonic acid | multiple interactions | EXP | | 6480464 | Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]] | CTD | PMID:14500290 | mevalonic acid | multiple interactions | ISO | RGD:1307751 | 6480464 | Mevalonic Acid inhibits the reaction [atorvastatin results in increased expression of SREBF2 mRNA]; more ... | CTD | PMID:12056585 | mono(2-ethylhexyl) phthalate | increases expression | EXP | | 6480464 | mono-(2-ethylhexyl)phthalate results in increased expression of SREBF2 mRNA | CTD | PMID:23118965 | olanzapine | multiple interactions | EXP | | 6480464 | olanzapine results in increased cleavage of and results in increased activity of SREBF2 protein | CTD | PMID:17052361 | olanzapine | multiple interactions | ISO | RGD:1307751 | 6480464 | [olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in decreased expression of SREBF2 mRNA | CTD | PMID:23226405 | perfluorooctane-1-sulfonic acid | decreases expression | ISO | RGD:730973 | 6480464 | perfluorooctane sulfonic acid results in decreased expression of SREBF2 mRNA | CTD | PMID:20936131 | perfluorooctanoic acid | decreases expression | ISO | RGD:730973 | 6480464 | perfluorooctanoic acid results in decreased expression of SREBF2 mRNA | CTD | PMID:20936131 | pirinixic acid | decreases expression | ISO | RGD:1307751 | 6480464 | pirinixic acid results in decreased expression of SREBF2 protein; more ... | CTD | PMID:17126302 | quercetin 3-O-beta-D-glucoside | multiple interactions | EXP | | 6480464 | [isoquercitrin co-treated with Hydrogen Peroxide] results in increased cleavage of and results in increased activity of SREBF2 protein; more ... | CTD | PMID:18032389 | resveratrol | increases expression | EXP | | 6480464 | resveratrol results in increased expression of SREBF2 protein modified form | CTD | PMID:22153697 | resveratrol | multiple interactions | EXP | | 6480464 | 25-hydroxycholesterol inhibits the reaction [resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein]; more ... | CTD | PMID:22153697 | selenium atom | increases expression | EXP | | 6480464 | Selenium results in increased expression of SREBF2 mRNA | CTD | PMID:19244175 | simvastatin | multiple interactions | EXP | | 6480464 | Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]] | CTD | PMID:14500290 | simvastatin | increases expression | ISO | RGD:1307751 | 6480464 | Simvastatin results in increased expression of SREBF2 mRNA | CTD | PMID:12056585 | simvastatin | multiple interactions | ISO | RGD:1307751 | 6480464 | Simvastatin results in increased activity of and results in increased localization of SREBF2 protein; more ... | CTD | PMID:12056585 | simvastatin | increases expression | EXP | | 6480464 | Simvastatin results in increased expression of SREBF2 protein modified form | CTD | PMID:20018177 | testosterone | increases expression | ISO | RGD:730973 | 6480464 | Testosterone results in increased expression of SREBF2 mRNA | CTD | PMID:16579987 | trans-resveratrol | increases expression | EXP | | 6480464 | resveratrol results in increased expression of SREBF2 protein modified form | CTD | PMID:22153697 | trans-resveratrol | multiple interactions | EXP | | 6480464 | 25-hydroxycholesterol inhibits the reaction [resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein]; more ... | CTD | PMID:22153697 | trimellitic anhydride | increases expression | ISO | RGD:730973 | 6480464 | trimellitic anhydride results in increased expression of SREBF2 mRNA | CTD | PMID:19042947 | troglitazone | multiple interactions | EXP | | 6480464 | [troglitazone binds to and results in increased activity of PPARG protein] which results in decreased expression of SREBF2 mRNA; more ... | CTD | PMID:16946405 | valproic acid | affects expression | ISO | RGD:730973 | 6480464 | Valproic Acid affects the expression of SREBF2 mRNA | CTD | PMID:17963808 | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene Ontology Annotations
Molecular Pathway Annotations
Phenotype Annotations
Disease Annotations
|
|
|
Gene-Chemical Interaction Annotations
Gene Ontology Annotations
|
|
|
|
|
|
|
|
Molecular Pathway Annotations
Phenotype Annotations
References - curated| 1. |
Boizard M, etal., J Biol Chem. 1998 Oct 30;273(44):29164-71. |
| 2. |
Chmielewski M, etal., Atherosclerosis. 2007 Apr;191(2):326-32. Epub 2006 Jun 30. |
| 3. |
Cho EJ, etal., J Pharm Pharmacol. 2007 May;59(5):687-94. |
| 4. |
Duan X, etal., J Lipid Res. 2005 Feb;46(2):252-7. Epub 2004 Nov 16. |
| 5. |
Ettinger SL, etal., Cancer Res. 2004 Mar 15;64(6):2212-21. |
| 6. |
GOA_HUMAN data from the GO Consortium |
| 7. |
Ishikawa M, etal., J Lipid Res. 2008 Dec;49(12):2524-34. Epub 2008 Aug 5. |
| 8. |
Jiang T, etal., J Am Soc Nephrol. 2005 Aug;16(8):2385-94. Epub 2005 Jun 8. |
| 9. |
Jiang T, etal., Kidney Int. 2005 Dec;68(6):2608-20. |
| 10. |
Kim HJ and Vaziri ND, Am J Nephrol. 2009 Jan 16;29(6):607-614. |
| 11. |
Kim JH and Ong WY, J Chem Neuroanat. 2009 Mar;37(2):71-7. Epub 2008 Dec 13. |
| 12. |
Kim Y, etal., Am J Med Genet B Neuropsychiatr Genet. 2005 Nov 5;139(1):19-22. |
| 13. |
MacLean PS, etal., J Clin Endocrinol Metab. 2005 Apr;90(4):2250-8. Epub 2005 Jan 11. |
| 14. |
Marseille-Tremblay C, etal., Mol Reprod Dev. 2008 Jun;75(6):1054-62. |
| 15. |
Muller PY and Miserez AR, J Med Genet. 2002 Apr;39(4):271-5. |
| 16. |
Osborne TF and Espenshade PJ, Genes Dev. 2009 Nov 15;23(22):2578-91. |
| 17. |
Pallottini V, etal., J Cell Biochem. 2006 Aug 1;98(5):1044-53. |
| 18. |
Proctor G, etal., Diabetes. 2006 Sep;55(9):2502-9. |
| 19. |
RGD automated import pipeline for gene-chemical interactions |
| 20. |
Robinet P, etal., Atherosclerosis. 2003 Jun;168(2):381-7. |
| 21. |
Wang Z, etal., Diabetes. 2005 Aug;54(8):2328-35. |
| 22. |
Wu J, etal., Am J Physiol. 1999 Dec;277(6 Pt 1):E1087-94. |
| 23. |
Xu G, etal., Biochim Biophys Acta. 2004 Apr 5;1688(3):274-9. |
References - uncurated| PubMed | 10397761 |
| 10591208 | |
| 10619424 | |
| 10627507 | |
| 10896675 | |
| 10976766 | |
| 11149418 | |
| 11283257 | |
| 11485982 | |
| 12202038 | |
| 12242332 | |
| 12446768 | |
| 12477932 | |
| 12615929 | |
| 12842885 | |
| 12855700 | |
| 12941800 | |
| 14500290 | |
| 14645851 | |
| 14702039 | |
| 14765107 | |
| 14988395 | |
| 15085196 | |
| 15211801 | |
| 15358760 | |
| 15388640 | |
| 15461802 | |
| 15489334 | |
| 15527767 | |
| 15721010 | |
| 15798184 | |
| 16014965 | |
| 16141315 | |
| 16158080 | |
| 16169070 | |
| 16227610 | |
| 16303770 | |
| 16335799 | |
| 16466730 | |
| 16697011 | |
| 16763159 | |
| 16806233 | |
| 16901265 | |
| 17008555 | |
| 17142457 | |
| 17198935 | |
| 17383658 | |
| 17604677 | |
| 17702963 | |
| 17921436 | |
| 18032389 | |
| 18072016 | |
| 18195716 | |
| 18272927 | |
| 18321953 | |
| 18403372 | |
| 18579430 | |
| 18660489 | |
| 18936756 | |
| 18954446 | |
| 18959802 | |
| 19041766 | |
| 19056482 | |
| 19098903 | |
| 19116028 | |
| 19155782 | |
| 19231010 | |
| 19263511 | |
| 19323650 | |
| 19460711 | |
| 19497963 | |
| 19550366 | |
| 19582494 | |
| 19706601 | |
| 19740467 | |
| 19906111 | |
| 19913121 | |
| 19948975 | |
| 20031551 | |
| 20111910 | |
| 20138239 | |
| 20144195 | |
| 20167577 | |
| 20211142 | |
| 20379614 | |
| 20450493 | |
| 20460578 | |
| 20466882 | |
| 20566875 | |
| 20628086 | |
| 20732877 | |
| 20734064 | |
| 20926756 | |
| 20936779 | |
| 20965718 | |
| 20980003 | |
| 21139048 | |
| 21613400 | |
| 21693764 | |
| 21757058 | |
| 21906983 | |
| 21944868 | |
| 21963094 | |
| 21987572 | |
| 21988832 | |
| 22153697 | |
| 22182810 | |
| 22288532 | |
| 22425645 | |
| 22429355 | |
| 22505724 | |
| 22573382 | |
| 22573671 | |
| 22662110 | |
| 22666465 | |
| 23044239 | |
| 7759101 | |
| 7903453 | |
| 8402897 | |
| 8605870 | |
| 8626610 | |
| 8643593 | |
| 8900111 | |
| 8918891 | |
| 9070916 | |
| 9139737 | |
| 9242699 | |
| 9508001 | |
| 9927745 | |
| 9990022 |
RGD Disease Portals| SREBF2 has been annotated in the following RGD Disease Portals. |
|||||||||
![]() |
| ||||||||
![]() |
| ||||||||
![]() |
| ||||||||
![]() |
| ||||||||
![]() |
| ||||||||
![]() |
| ||||||||
![]() |
| ||||||||
Comparative Map Data| SREBF2 (Homo sapiens) |
|
|||||||||||||||||||||||||||||||||||
| Srebf2 (Mus musculus) |
|
|||||||||||||||||||||||||||||||||||
| Srebf2 (Rattus norvegicus) |
|
Position Markers| D22S1157 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| SHGC-30242 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| SHGC-58081 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| SHGC-12896 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| RH80373 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| RH102651 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| GDB:592857 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| WI-20973 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| D22S1563 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| 1094 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| AL008656 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| WI-12706 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| SHGC-12896 |
|
QTLs in Region (Human Genome Assembly GRCh37)| The following QTLs overlap with this region. | ![]() | Full Report | ![]() | CSV | ![]() | TAB | ![]() | Printer | ![]() | Gviewer |
Nucleotide Sequences| Nucleotide RefSeqs | NM_004599 | (Get FASTA) | Search GEO for Microarray Profiles |
| GenBank Nucleotide | ABBA01055654 | (Get FASTA) | Search GEO for Microarray Profiles |
| ABBA01055655 | (Get FASTA) | Search GEO for Microarray Profiles | |
| AK299914 | (Get FASTA) | Search GEO for Microarray Profiles | |
| AL021453 | (Get FASTA) | Search GEO for Microarray Profiles | |
| AL834221 | (Get FASTA) | Search GEO for Microarray Profiles | |
| AMYH01012804 | (Get FASTA) | Search GEO for Microarray Profiles | |
| BC051385 | (Get FASTA) | Search GEO for Microarray Profiles | |
| BC051799 | (Get FASTA) | Search GEO for Microarray Profiles | |
| BC056158 | (Get FASTA) | Search GEO for Microarray Profiles | |
| CH471095 | (Get FASTA) | Search GEO for Microarray Profiles | |
| CT841522 | (Get FASTA) | Search GEO for Microarray Profiles | |
| D86746 | (Get FASTA) | Search GEO for Microarray Profiles | |
| U02031 | (Get FASTA) | Search GEO for Microarray Profiles | |
| Z99716 | (Get FASTA) | Search GEO for Microarray Profiles |
| RefSeq Acc Id: | NM_004599 | |||||||||||||||||||||||||
| RefSeq Status: | REVIEWED | |||||||||||||||||||||||||
| Type: | CODING | |||||||||||||||||||||||||
| Protein Acc Id: | NP_004590 | |||||||||||||||||||||||||
| Position: |
|
Protein Sequences| Protein RefSeqs | NP_004590 | (Get FASTA) |
| GenBank Protein | AAA50746 | (Get FASTA) |
| AAH51385 | (Get FASTA) | |
| AAH51799 | (Get FASTA) | |
| AAH56158 | (Get FASTA) | |
| BAC57590 | (Get FASTA) | |
| BAG61752 | (Get FASTA) | |
| CAD38902 | (Get FASTA) | |
| CAJ86452 | (Get FASTA) | |
| CAK54615 | (Get FASTA) | |
| CAK54914 | (Get FASTA) | |
| EAW60469 | (Get FASTA) | |
| EAW60470 | (Get FASTA) | |
| EAW60471 | (Get FASTA) | |
| Q12772 | (Get FASTA) |
Promoters| RGD ID: | 6800384 | ||||||||||
| Promoter ID: | HG_KWN:43019 | ||||||||||
| Type: | CpG-Island | ||||||||||
| SO ACC ID: | SO:0000170 | ||||||||||
| Source: | MPROMDB | ||||||||||
| Tissues & Cell Lines: | CD4+TCell, CD4+TCell_12Hour, CD4+TCell_2Hour, HeLa_S3, Jurkat, K562, Lymphoblastoid, NB4 | ||||||||||
| Transcripts: | OTTHUMT00000321956, OTTHUMT00000321957 | ||||||||||
| Position: |
|
| RGD ID: | 6800391 | ||||||||||
| Promoter ID: | HG_KWN:43022 | ||||||||||
| Type: | Non-CpG | ||||||||||
| SO ACC ID: | SO:0000170 | ||||||||||
| Source: | MPROMDB | ||||||||||
| Tissues & Cell Lines: | CD4+TCell, Lymphoblastoid | ||||||||||
| Transcripts: | OTTHUMT00000321963 | ||||||||||
| Position: |
|
| RGD ID: | 6800389 | ||||||||||
| Promoter ID: | HG_KWN:43023 | ||||||||||
| Type: | Non-CpG | ||||||||||
| SO ACC ID: | SO:0000170 | ||||||||||
| Source: | MPROMDB | ||||||||||
| Tissues & Cell Lines: | Lymphoblastoid | ||||||||||
| Transcripts: | OTTHUMT00000321962 | ||||||||||
| Position: |
|
| RGD ID: | 6812233 | ||||||||||
| Promoter ID: | HG_ACW:52242 | ||||||||||
| Type: | Non-CpG | ||||||||||
| SO ACC ID: | SO:0000170 | ||||||||||
| Source: | MPROMDB | ||||||||||
| Tissues & Cell Lines: | Lymphoblastoid | ||||||||||
| Transcripts: | SREBF2.FAPR07, SREBF2.HAPR07, SREBF2.IAPR07-UNSPLICED, TARPA.AAPR07-UNSPLICED | ||||||||||
| Position: |
|
| RGD ID: | 6800383 | ||||||||||
| Promoter ID: | HG_KWN:43024 | ||||||||||
| Type: | Non-CpG | ||||||||||
| SO ACC ID: | SO:0000170 | ||||||||||
| Source: | MPROMDB | ||||||||||
| Tissues & Cell Lines: | Jurkat, Lymphoblastoid | ||||||||||
| Transcripts: | OTTHUMT00000321958 | ||||||||||
| Position: |
|
| RGD ID: | 6800390 | ||||||||||
| Promoter ID: | HG_KWN:43025 | ||||||||||
| Type: | Non-CpG | ||||||||||
| SO ACC ID: | SO:0000170 | ||||||||||
| Source: | MPROMDB | ||||||||||
| Tissues & Cell Lines: | Lymphoblastoid | ||||||||||
| Transcripts: | OTTHUMT00000321961 | ||||||||||
| Position: |
|
| RGD ID: | 6800386 | ||||||||||
| Promoter ID: | HG_KWN:43026 | ||||||||||
| Type: | Non-CpG | ||||||||||
| SO ACC ID: | SO:0000170 | ||||||||||
| Source: | MPROMDB | ||||||||||
| Tissues & Cell Lines: | K562, Lymphoblastoid | ||||||||||
| Transcripts: | OTTHUMT00000321960 | ||||||||||
| Position: |
|
| RGD ID: | 6800385 | ||||||||||
| Promoter ID: | HG_KWN:43027 | ||||||||||
| Type: | Non-CpG | ||||||||||
| SO ACC ID: | SO:0000170 | ||||||||||
| Source: | MPROMDB | ||||||||||
| Tissues & Cell Lines: | HeLa_S3, K562, Lymphoblastoid | ||||||||||
| Transcripts: | OTTHUMT00000321959 | ||||||||||
| Position: |
|
| RGD ID: | 6800392 | ||||||||||
| Promoter ID: | HG_KWN:43028 | ||||||||||
| Type: | CpG-Island | ||||||||||
| SO ACC ID: | SO:0000170 | ||||||||||
| Source: | MPROMDB | ||||||||||
| Tissues & Cell Lines: | CD4+TCell, HeLa_S3, K562, Lymphoblastoid, NB4 | ||||||||||
| Transcripts: | UC003BBK.1 | ||||||||||
| Position: |
|
| RGD ID: | 6872278 | ||||||||||
| Promoter ID: | EPDNEW_H9304 | ||||||||||
| Type: | initiation region | ||||||||||
| Name: | QRSL1_1 | ||||||||||
| Description: | glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1 | ||||||||||
| SO ACC ID: | SO:0000170 | ||||||||||
| Source: | EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/) | ||||||||||
| Position: |
|
External Database Links| Database | Acc Id | Source(s) |
| COSMIC | SREBF2 | COSMIC |
| Ensembl Genes | ENSG00000198911 | ENTREZGENE |
| Ensembl Protein | ENSP00000354476 | ENTREZGENE |
| Ensembl Transcript | ENST00000361204 | ENTREZGENE |
| Entrez Gene | 6721 | ENTREZGENE |
| Gene3D-CATH | HLH_DNA_bd | UniProtKB/Swiss-Prot |
| HGNC ID | 11290 | ENTREZGENE |
| HomoloGene Group ID | 20966 | ENTREZGENE |
| HPRD ID | 02726 | ENTREZGENE |
| InterPro | HLH_DNA-bd | UniProtKB/Swiss-Prot |
| IPI | IPI00328793 | UniProtKB/Swiss-Prot |
| IPI01014321 | UniProtKB/TrEMBL | |
| KEGG Report | hsa:6721 | ENTREZGENE, UniProtKB/Swiss-Prot |
| OMIM | 600481 | OMIM |
| Pfam | HLH | UniProtKB/Swiss-Prot |
| PharmGKB | PA336 | PharmGKB |
| PROSITE | HLH | UniProtKB/Swiss-Prot |
| SMART | HLH | UniProtKB/Swiss-Prot |
| Superfamily-SCOP | HLH_basic | UniProtKB/Swiss-Prot |
| UniGene | Hs.443258 | ENTREZGENE |
| UniProt | G3V0I8_HUMAN | UniProtKB/TrEMBL |
| H0Y7E5_HUMAN | UniProtKB/TrEMBL | |
| Q8NCY3_HUMAN | UniProtKB/TrEMBL | |
| SRBP2_HUMAN | UniProtKB/Swiss-Prot |
Nomenclature History| Date | Current Symbol | Current Name | Previous Symbol | Previous Name | Description | Reference | Status |
|---|---|---|---|---|---|---|---|
| 2011-08-16 | SREBF2 | sterol regulatory element binding transcription factor 2 | SREBF2 | sterol regulatory element binding transcription factor 2 | Symbol and/or name change | 39860 | APPROVED |
| More on SREBF2 | |||
![]() |
Entrez Gene | ||
![]() |
Ensembl Gene | ||
|
|
||
![]() |
HGNC Report | ||
![]() |
NCBI Map Viewer | ||
![]() |
Vista | ||
![]() |
Vista + UCSC | ||
| RGD Object Information | |
| RGD ID: | 730972 |
| Created: | 2003-12-10 |
| Species: | Homo sapiens |
| Last Modified: | 2013-04-16 |
| Status: | ACTIVE |
© Bioinformatics Program, HMGC at the Medical College of Wisconsin
RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.




